Actively Recruiting
Observational Study of Amivantamab and Chemotherapy in Adults with Metastatic Non-Small Cell Lung Cancer with EGFR Mutations
Led by GFPC Investigation · Updated on 2026-05-01
100
Participants Needed
16
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying adults with metastatic non-small cell lung cancer NSCLC who have specific mutations in the EGFR gene. The study aims to understand how well the combination of amivantamab and platinum-based chemotherapy works and how safe it is in real-life settings. There are two groups one receiving this combination as their first treatment for an EGFR exon 20 insertion mutation, and another receiving it after prior treatment with osimertinib for EGFR exon 19 or 21 mutations. This observational study does not involve new treatments but collects information from people receiving amivantamab and chemotherapy through an early access program. Group A includes those treated initially with this combination, while Group B includes those treated after osimertinib. Participants continue their usual care and the study gathers medical data without extra tests or procedures. The study runs from March 21, 2024, to October 21, 2025. Participants will be followed by their regular oncologist, and the study will collect data on how long the treatment prevents cancer progression or death over a two-year period. Researchers will also monitor overall survival, response rates, side effects, treatment duration, and progression details. No additional visits or procedures are required beyond normal medical care, and the study uses information from standard clinical evaluations and records.
CONDITIONS
Brief Title
Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer
Research Team
P
Prof. Laurent Greillier
S
Soizic Ferlandin
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here